Francois Brisebois
Stock Analyst at Oppenheimer
(1.94)
# 3,146
Out of 4,969 analysts
89
Total ratings
37.5%
Success rate
-8.06%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SVRA Savara | Maintains: Outperform | $5 → $6 | $3.42 | +75.70% | 5 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $8.67 | +822.72% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $6.96 | +129.89% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $1.33 | +201.89% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $57.69 | +24.80% | 7 | Jan 22, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $37.53 | +62.54% | 6 | Jan 13, 2025 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $9.06 | +120.75% | 4 | Dec 17, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $5.31 | +427.31% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $14.64 | +104.92% | 8 | Oct 31, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $46.70 | +249.04% | 4 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $13.48 | +308.01% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $15.14 | -0.92% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $5.30 | +13.31% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $2.86 | +284.62% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $15.91 | -12.01% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $15 | $3.95 | +280.23% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.17 | +688.64% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $14.37 | +352.49% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $5.85 | +71.09% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $1.94 | +158.40% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $6.01 | +2,429.12% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $16.55 | +117.52% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $60 | $0.19 | +31,865.90% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $3.90 | +138,361.54% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $3.42 | +221.64% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $3.57 | +404.20% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $4.71 | +961.57% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $1.28 | +253,025.00% | 1 | Feb 4, 2020 |
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $3.42
Upside: +75.70%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $8.67
Upside: +822.72%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $6.96
Upside: +129.89%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $1.33
Upside: +201.89%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $57.69
Upside: +24.80%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $37.53
Upside: +62.54%
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $9.06
Upside: +120.75%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $5.31
Upside: +427.31%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $14.64
Upside: +104.92%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $46.70
Upside: +249.04%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $13.48
Upside: +308.01%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $15.14
Upside: -0.92%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $5.30
Upside: +13.31%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $2.86
Upside: +284.62%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $15.91
Upside: -12.01%
Aug 9, 2024
Maintains: Outperform
Price Target: $13 → $15
Current: $3.95
Upside: +280.23%
Jun 25, 2024
Initiates: Outperform
Price Target: $25
Current: $3.17
Upside: +688.64%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $14.37
Upside: +352.49%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $5.85
Upside: +71.09%
Apr 1, 2024
Reiterates: Outperform
Price Target: $5
Current: $1.94
Upside: +158.40%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $6.01
Upside: +2,429.12%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $16.55
Upside: +117.52%
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $0.19
Upside: +31,865.90%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $3.90
Upside: +138,361.54%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $3.42
Upside: +221.64%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $3.57
Upside: +404.20%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $4.71
Upside: +961.57%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $1.28
Upside: +253,025.00%